Recipharm, a global contract development and manufacturing organisation (CDMO), is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a leading position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and […]

The post Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics first appeared on World Pharma Today.